Update on the Mechanism of Action of Topical Prostaglandins for Intraocular Pressure Reduction

Survey of Ophthalmology

Volumn 53, Issue 6 SUPPL., 2008, Pages

  Toris, Carol B ^a   Gabelt, B'Ann T ^b   Kaufman, Paul L ^b  

^a UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^b UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

Author keywords

aqueous humor; intraocular pressure; matrix metalloproteinases; prostaglandin; trabecular outflow; uveoscleral outflow

Indexed keywords

15 KETO LATANOPROST; 17 PHENYLTRINOR 8 ISOPROSTAGLANDIN E2; 2 [4 (1 HYDROXYHEXYL)PHENYL] 5 OXOCYCLOPENTANEHEPTANOIC ACID; 3,7 DITHIA PROSTAGLANDIN E1; 8 ISOPROSTAGLANDIN E2; AL 6598; BIMATOPROST; BUTAPROST; DOPAMINE RECEPTOR STIMULATING AGENT; LATANOPROST; MATRIX METALLOPROTEINASE; PROSTAGLANDIN DERIVATIVE; SULPROSTONE; TAFLUPROST; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TISSUE INHIBITOR OF METALLOPROTEINASE 2; TISSUE INHIBITOR OF METALLOPROTEINASE 3; TISSUE INHIBITOR OF METALLOPROTEINASE 4; TRAVOPROST; UNCLASSIFIED DRUG; UNOPROSTONE ISOPROPYL ESTER;

AQUEOUS HUMOR FLOW; ARTICLE; DRUG BINDING; DRUG EFFICACY; DRUG MECHANISM; GENETIC ANALYSIS; GLAUCOMA; HUMAN; IMMUNOHISTOCHEMISTRY; INTRAOCULAR PRESSURE; NONHUMAN; PRIORITY JOURNAL;

ADMINISTRATION, TOPICAL; ANIMALS; ANTIHYPERTENSIVE AGENTS; AQUEOUS HUMOR; GLAUCOMA, OPEN-ANGLE; HUMANS; INTRAOCULAR PRESSURE; OCULAR HYPERTENSION; PROSTAGLANDINS F, SYNTHETIC;

EID: 56449090612     PISSN: 00396257     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.survophthal.2008.08.010     Document Type: Article

References (90)

1. Aihara M., Lindsey J.D., and Weinreb R.N. Aqueous humor dynamics in mice. Invest Ophthalmol Vis Sci 44 (2003) 5168-5173
2. Alexander J.P., Samples J.R., Van Buskirk E.M., et al. Expression of matrix metalloproteinases and inhibitor by human trabecular meshwork. Invest Ophthalmol Vis Sci 32 (1991) 172-180
3. Anthony T.L., Lindsey J.D., Aihara M., et al. Detection of prostaglandin EP(1), EP(2), and FP receptor subtypes in human sclera. Invest Ophthalmol Vis Sci 42 (2001) 3182-3186
4. Anthony T.L., Lindsey J.D., and Weinreb R.N. Latanoprost's effects on TIMP-1 and TIMP-2 expression in human ciliary muscle cells. Invest Ophthalmol Vis Sci 43 (2002) 3705-3711
5. Anthony T.L., Pierce K.L., Stamer W.D., et al. Prostaglandin F2 alpha receptors in the human trabecular meshwork. Invest Ophthalmol Vis Sci 39 (1998) 315-321
6. Bahler C.K., Howell K.G., Hann C.R., et al. Prostaglandins increase trabecular meshwork outflow facility in cultured human anterior segments. Am J Ophthalmol 145 (2008) 114-119
7. Bean G.W., Camras C.B., et al. Commercially Available Prostaglandin Analogs for the Reduction of Intraocular Pressure - Similarities and Differences. Surv Ophthalmol 53 Suppl 1 (2008) S69-S84
8. Bill A. Further studies on the influence of the intraocular pressure on aqueous humor dynamics in cynomolgus monkeys. Invest Ophthalmol 6 (1967) 364-372
9. Bradley J.M., Vranka J., Colvis C.M., et al. Effect of matrix metalloproteinases activity on outflow in perfused human organ culture. Invest Ophthalmol Vis Sci 39 (1998) 2649-2658
10. Brew K., Dinakarpandian D., and Nagase H. Tissue inhibitors of metalloproteinases: evolution, structure and function. Biochim Biophys Acta 1477 (2000) 267-283
11. Brubaker R.F., Schoff E.O., Nau C.B., et al. Effects of AGN 192024, a new ocular hypotensive agent, on aqueous dynamics. Am J Ophthalmol 131 (2001) 19-24
12. Bulin C., Albrecht U., Bode J.G., et al. Differential effects of vasodilatory prostaglandins on focal adhesions, cytoskeletal architecture, and migration in human aortic smooth muscle cells. Arterioscler Thromb Vasc Biol 25 (2005) 84-89
13. Camras C.B., and Podos S.M. The role of endogenous prostaglandin in clinically-used and investigational glaucoma therapy, in Bito LZ, Stjernschantz J: The Ocular Effects of Prostaglandins and Other Eicosanoids (1989), Alan R. Liss, Inc, New York, NY pp 459-75
14. Camras C.B., Toris C.B., Sjoquist B., et al. Detection of the free acid of bimatoprost in aqueous humor samples from human eyes treated with bimatoprost before cataract surgery. Ophthalmology 111 (2004) 2193-2198
15. Cantor L.B., Hoop J., Wudunn D., et al. Levels of bimatoprost acid in the aqueous humour after bimatoprost treatment of patients with cataract. Br J Ophthalmol 91 (2007) 629-632
16. Christiansen G.A., Nau C.B., McLaren J.W., et al. Mechanism of ocular hypotensive action of bimatoprost (Lumigan) in patients with ocular hypertension or glaucoma. Ophthalmology 111 (2004) 1658-1662
17. Coleman R.A., Grix S.P., Head S.A., et al. A novel inhibitory prostanoid receptor in piglet saphenous vein. Prostaglandins 47 (1994) 151-168
18. Crowston J.G., Aihara M., Lindsey J.D., et al. Effect of latanoprost on outflow facility in the mouse. Invest Ophthalmol Vis Sci 45 (2004) 2240-2245
19. Dijkstra B.G., Schneemann A., and Hoyng P.F. Flow after prostaglandin E1 is mediated by receptor-coupled adenylyl cyclase in human anterior segments. Invest Ophthalmol Vis Sci 40 (1999) 2622-2626
20. Dinslage S., Hueber A., Diestelhorst M., et al. The influence of Latanoprost 0.005% on aqueous humor flow and outflow facility in glaucoma patients: a double-masked placebo-controlled clinical study. Graefes Arch Clin Exp Ophthalmol 242 (2004) 654-660
21. Eisenberg D. Latanoprost versus bimatoprost. Ophthalmology 110 (1862) 2003 1861-2; author reply
22. Gabelt B.T., and Kaufman P.L. The effect of prostaglandin F2 alpha on trabecular outflow facility in cynomolgus monkeys. Exp Eye Res 51 (1990) 87-91
23. Gabelt B.T., Seeman J.L., Podos S.M., et al. Aqueous humor dynamics in monkeys after topical 8-iso PGE(2). Invest Ophthalmol Vis Sci 45 (2004) 892-899
24. Gandolfi S.A., and Cimino L. Effect of bimatoprost on patients with primary open-angle glaucoma or ocular hypertension who are nonresponders to latanoprost. Ophthalmology 110 (2003) 609-614
25. Gaton D.D., Sagara T., Lindsey J.D., et al. Increased matrix metalloproteinases 1, 2, and 3 in the monkey uveoscleral outflow pathway after topical prostaglandin F(2 alpha)-isopropyl ester treatment. Arch Ophthalmol 119 (2001) 1165-1170
26. Haria M., and Spencer C.M. Unoprostone (isopropyl unoprostone). Drugs Aging 9 (1996) 213-218 discussion 219-20
27. Hinz B., Rösch S., Ramer R., et al. Latanoprost induces matrix metalloproteinase-1 expression in human nonpigmented ciliary epithelial cells through a cyclooxygenase-2-dependent mechanism. FASEB J 19 (2005) 1929-1931
28. Husain S., Jafri F., and Crosson C.E. Acute effects of PGF2alpha on MMP-2 secretion from human ciliary muscle cells: a PKC- and ERK-dependent process. Invest Ophthalmol Vis Sci 46 (2005) 1706-1713
29. Husain S., Whitlock N.A., Rice D.S., et al. Effects of latanoprost on rodent intraocular pressure. Exp Eye Res 83 (2006) 1453-1458
30. John S.W., Hagaman J.R., MacTaggart T.E., et al. Intraocular pressure in inbred mouse strains. Invest Ophthalmol Vis Sci 38 (1997) 249-253
31. Johnson T.V., Fan S., and Toris C.B. Rebound tonometry in conscious, conditioned mice avoids the acute and profound effects of anesthesia on intraocular pressure. J Ocul Pharmacol Ther 24 (2008) 175-185
32. Kamphuis W., Schneemann A., van Beek L.M., et al. Prostanoid receptor gene expression profile in human trabecular meshwork: a quantitative real-time PCR approach. Invest Ophthalmol Vis Sci 42 (2001) 3209-3215
33. Kim J.W., Lindsey J.D., Wang N., et al. Increased human scleral permeability with prostaglandin exposure. Invest Ophthalmol Vis Sci 42 (2001) 1514-1521
34. Krebs W., and Krebs I.P. Ultrastructural evidence for lymphatic capillaries in the primate choroid. Arch Ophthalmol 106 (1988) 1615-1616
35. Lee P.Y., Podos S.M., and Severin C. Effect of prostaglandin F2 alpha on aqueous humor dynamics of rabbit, cat, and monkey. Invest Ophthalmol Vis Sci 25 (1984) 1087-1093
36. Liang Y., Li C., Guzman V.M., et al. Upregulation of orphan nuclear receptor Nur77 following PGF(2alpha), Bimatoprost, and Butaprost treatments. Essential role of a protein kinase C pathway involved in EP(2) receptor activated Nur77 gene transcription. Br J Pharmacol 142 (2004) 737-748
37. Liang Y., Li C., Guzman V.M., et al. Comparison of prostaglandin F2alpha, bimatoprost (prostamide), and butaprost (EP2 agonist) on Cyr61 and connective tissue growth factor gene expression. J Biol Chem 278 (2003) 27267-27277
38. Lim K.S., Nau C.B., O'Byrne M.M., et al. Mechanism of action of bimatoprost, latanoprost, and travoprost in healthy subjects. A crossover study. Ophthalmology 115 (2008) 790-795 e4
39. Lütjen-Drecoll E., and Tamm E. Morphological study of the anterior segment of cynomolgus monkey eyes following treatment with prostaglandin F2 alpha. Exp Eye Res 47 (1988) 761-769
40. Maihöfner C., Schlötzer-Schrehardt U., Gühring H., et al. Expression of cyclooxygenase-1 and -2 in normal and glaucomatous human eyes. Invest Ophthalmol Vis Sci 42 (2001) 2616-2624
41. Mishima H.K., Kiuchi Y., Takamatsu M., et al. Circadian intraocular pressure management with latanoprost: diurnal and nocturnal intraocular pressure reduction and increased uveoscleral outflow. Surv Ophthalmol 41 Suppl 2 (1997) S139-S144
42. Murphy G., and Docherty A.J. The matrix metalloproteinases and their inhibitors. Am J Respir Cell Mol Biol 7 (1992) 120-125
43. Negishi M., Sugimoto Y., Irie A., et al. Two isoforms of prostaglandin E receptor EP3 subtype. Different COOH-terminal domains determine sensitivity to agonist-induced desensitization. J Biol Chem 268 (1993) 9517-9521
44. Nilsson S.F., Drecoll E., Lütjen-Drecoll E., et al. The prostanoid EP2 receptor agonist butaprost increases uveoscleral outflow in the cynomolgus monkey. Invest Ophthalmol Vis Sci 47 (2006) 4042-4049
45. Ocklind A. Effect of latanoprost on the extracellular matrix of the ciliary muscle. A study on cultured cells and tissue sections. Exp Eye Res 67 (1998) 179-191
46. Oh D.J., Martin J.L., Williams A.J., et al. Analysis of expression of matrix metalloproteinases and tissue inhibitors of metalloproteinases in human ciliary body after latanoprost. Invest Ophthalmol Vis Sci 47 (2006) 953-963
47. Oh D.J., Martin J.L., Williams A.J., et al. Effect of latanoprost on the expression of matrix metalloproteinases and their tissue inhibitors in human trabecular meshwork cells. Invest Ophthalmol Vis Sci 47 (2006) 3887-3895
48. Ota T., Aihara M., Narumiya S., et al. The effects of prostaglandin analogues on IOP in prostanoid FP-receptor-deficient mice. Invest Ophthalmol Vis Sci 46 (2005) 4159-4163
49. Ota T., Aihara M., Saeki T., et al. The IOP-lowering effects and mechanism of action of tafluprost in prostanoid receptor-deficient mice. Br J Ophthalmol 91 (2007) 673-676
50. Ota T., Aihara M., Saeki T., et al. The effects of prostaglandin analogues on prostanoid EP1, EP2, and EP3 receptor-deficient mice. Invest Ophthalmol Vis Sci 47 (2006) 3395-3399
51. Poyer J.F., Millar C., and Kaufman P.L. Prostaglandin F2 alpha effects on isolated rhesus monkey ciliary muscle. Invest Ophthalmol Vis Sci 36 (1995) 2461-2465
52. Richter M., Krauss A.H., Woodward D.F., et al. Morphological changes in the anterior eye segment after long-term treatment with different receptor selective prostaglandin agonists and a prostamide. Invest Ophthalmol Vis Sci 44 (2003) 4419-4426
53. Sagara T., Gaton D.D., Lindsey J.D., et al. Topical prostaglandin F2alpha treatment reduces collagen types I, III, and IV in the monkey uveoscleral outflow pathway. Arch Ophthalmol 117 (1999) 794-801
54. Sakurai M., Higashide T., Takahashi M., et al. Association between genetic polymorphisms of the prostaglandin F2alpha receptor gene and response to latanoprost. Ophthalmology 114 (2007) 1039-1045
55. Schlotzer-Schrehardt U., and Zenkel M. Nüsing RM: Expression and localization of FP and EP prostanoid receptor subtypes in human ocular tissues. Invest Ophthalmol Vis Sci 43 (2002) 1475-1487
56. Sharif N.A., Crider J.Y., Husain S., et al. Human ciliary muscle cell responses to FP-class prostaglandin analogs: phosphoinositide hydrolysis, intracellular Ca2+ mobilization and MAP kinase activation. J Ocul Pharmacol Ther 19 (2003) 437-455
57. Sharif N.A., Kelly C.R., Crider J.Y., et al. Ocular hypotensive FP prostaglandin (PG) analogs: PG receptor subtype binding affinities and selectivities, and agonist potencies at FP and other PG receptors in cultured cells. J Ocul Pharmacol Ther 19 (2003) 501-515
58. Sharif N.A., Kelly C.R., and Crider J.Y. Human trabecular meshwork cell responses induced by bimatoprost, travoprost, unoprostone, and other FP prostaglandin receptor agonist analogues. Invest Ophthalmol Vis Sci 44 (2003) 715-721
59. Spada C.S., Krauss A.H., Woodward D.F., et al. Bimatoprost and prostaglandin F(2 alpha) selectively stimulate intracellular calcium signaling in different cat iris sphincter cells. Exp Eye Res 80 (2005) 135-145
60. Stjernschantz J., Selén G., Ocklind A., and Resul B. Weinreb RN: Uveoscleral Outflow. Biology and Clinical Aspects. Effects of latanoprost and related prostaglandin analogues, in Alm A (1998), Mosby International Limited, London, UK pp 57-72
61. Stumpff F., Boxberger M., Krauss A., et al. Stimulation of cannabinoid (CB1) and prostanoid (EP2) receptors opens BKCa channels and relaxes ocular trabecular meshwork. Exp Eye Res 80 (2005) 697-708
62. Takagi Y., Nakajima T., Shimazaki A., et al. Pharmacological characteristics of AFP-168 (tafluprost), a new prostanoid FP receptor agonist, as an ocular hypotensive drug. Exp Eye Res 78 (2004) 767-776
63. Tamm E., and Rittig M. Lütjen-Drecoll E: [Electron microscopy and immunohistochemical studies of the intraocular pressure lowering effect of prostaglandin F2 alpha]. Fortschr Ophthalmol 87 (1990) 623-629
64. Thieme H., Schimmat C., Münzer G., et al. Endothelin antagonism: effects of FP receptor agonists prostaglandin F2alpha and fluprostenol on trabecular meshwork contractility. Invest Ophthalmol Vis Sci 47 (2006) 938-945
65. Thieme H., Steinhausen K., Ottlecz A., et al. Effects of unoprostone and endothelin 1 on L-type channel currents in human trabecular meshwork cells. Ophthalmic Res 37 (2005) 293-300
66. Thieme H., Stumpff F., Ottlecz A., et al. Mechanisms of action of unoprostone on trabecular meshwork contractility. Invest Ophthalmol Vis Sci 42 (2001) 3193-3201
67. Toris C.B., Camras C.B., Yablonski M.E., et al. Effects of exogenous prostaglandins on aqueous humor dynamics and blood-aqueous barrier function. Surv Ophthalmol 41 Suppl 2 (1997) S69-S75
68. Toris C.B., and Pederson J.E. Effect of intraocular pressure on uveoscleral outflow following cyclodialysis in the monkey eye. Invest Ophthalmol Vis Sci 26 (1985) 1745-1749
69. Toris C.B., Zhan G., and Camras C.B. Increase in outflow facility with unoprostone treatment in ocular hypertensive patients. Arch Ophthalmol 122 (2004) 1782-1787
70. Toris C.B., Zhan G., Fan S., et al. Effects of travoprost on aqueous humor dynamics in patients with elevated intraocular pressure. J Glaucoma 16 (2007) 189-195
71. Toris C.B., Zhan G.L., Camras C.B., et al. Effects of travoprost on aqueous humor dynamics in monkeys. J Glaucoma 14 (2005) 70-73
72. Toris C.B., Zhan G.L., Feilmeier M.R., et al. Effects of a prostaglandin DP receptor agonist, AL-6598, on aqueous humor dynamics in a nonhuman primate model of glaucoma. J Ocul Pharmacol Ther 22 (2006) 86-92
73. Toris C.B., Zhan G.L., Zhao J., et al. Potential mechanism for the additivity of pilocarpine and latanoprost. Am J Ophthalmol 131 (2001) 722-728
74. Vaajanen A., Vapaatalo H., and Oksala O. A modified in vitro method for aqueous humor outflow studies in enucleated porcine eyes. J Ocul Pharmacol Ther 23 (2007) 124-131
75. Van Alphen G.W.H.M., Wilhelm P.B., and Elsenfeld P.W. The effect of prostaglandins on the isolated internal muscles of the mammalian eye, including man. Doc Ophthalmol 42 (1977) 397-415
76. Wan Z., Woodward D.F., Cornell C.L., et al. Bimatoprost, prostamide activity, and conventional drainage. Invest Ophthalmol Vis Sci 48 (2007) 4107-4115
77. Wang R.F., Gagliuso D.J., Mittag T.W., et al. Effect of 15-keto latanoprost on intraocular pressure and aqueous humor dynamics in monkey eyes. Invest Ophthalmol Vis Sci 48 (2007) 4143-4147
78. Wang R.F., Lee P.Y., Mittag T.W., et al. Effect of 8-iso prostaglandin E2 on aqueous humor dynamics in monkeys. Arch Ophthalmol 116 (1998) 1213-1216
79. Weinreb R.N. Enhancement of scleral macromolecular permeability with prostaglandins. Trans Am Ophthalmol Soc 99 (2001) 319-343
80. Weinreb R.N., Kashiwagi K., Kashiwagi F., et al. Prostaglandins increase matrix metalloproteinase release from human ciliary smooth muscle cells. Invest Ophthalmol Vis Sci 38 (1997) 2772-2780
81. Weinreb R.N., and Lindsey J.D. Metalloproteinase gene transcription in human ciliary muscle cells with latanoprost. Invest Ophthalmol Vis Sci 43 (2002) 716-722
82. Weinreb R.N., Lindsey J.D., Marchenko G., et al. Prostaglandin FP agonists alter metalloproteinase gene expression in sclera. Invest Ophthalmol Vis Sci 45 (2004) 4368-4377
83. Weinreb R.N., Mitchell M.D., and Polansky J.R. Prostaglandin production by human trabecular cells: in vitro inhibition by dexamethasone. Invest Ophthalmol Vis Sci 24 (1983) 1541-1545
84. Weinreb R.N., Polansky J.R., Alvarado J.A., et al. Arachidonic acid metabolism in human trabecular meshwork cells. Invest Ophthalmol Vis Sci 29 (1988) 1708-1712
85. Weinreb R.N., Toris C.B., Gabelt B.T., et al. Effects of prostaglandins on the aqueous humor outflow pathways. Surv Ophthalmol 47 Suppl 1 (2002) S53-S64
86. Woodward D.F., Krauss A.H., Chen J., et al. Pharmacological characterization of a novel antiglaucoma agent, Bimatoprost (AGN 192024). J Pharmacol Exp Ther 305 (2003) 772-785
87. Woodward D.F., Liang Y., and Krauss A.H. Prostamides (prostaglandin-ethanolamides) and their pharmacology. Br J Pharmacol 153 (2008) 410-419
88. Yamaji K., Yoshitomi T., Ishikawa H., et al. Prostaglandins E1 and E2, but not F2alpha or latanoprost, inhibit monkey ciliary muscle contraction. Curr Eye Res 30 (2005) 661-665
89. Yousufzai S.Y., and Ye Z. Abdel-Latif AA: Prostaglandin F2 alpha and its analogs induce release of endogenous prostaglandins in iris and ciliary muscles isolated from cat and other mammalian species. Exp Eye Res 63 (1996) 305-310
90. Zhao X., Pearson K.E., Stephan D.A., et al. Effects of prostaglandin analogues on human ciliary muscle and trabecular meshwork cells. Invest Ophthalmol Vis Sci 44 (2003) 1945-1952